Treatment-related cardiovascular toxicity in long-term survivors of testicular cancer
References
- Znaor A, Lortet-Tieulent J, Jemal A, Bray F. International variations and trends in testicular cancer incidence and mortality. Eur Urol 2014; 65:1095-106.
- Trabert B, Chen J, Devesa SS, Bray F, McGlynn KA. International patterns and trends in testicular cancer incidence, overall and by histologic subtype, 1973-2007. Andrology 2015; 3: 4-12.
- Kovač V. The cause of testicular cancer. Radiol Oncol 1998; 32: 201-5.
- National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. [citated 2 Feb 2016]. Available at https://seer.cancer.gov/ statfacts/htlm/testis.htlm
- Fossa SD, Gilbert E, Dores GM, Chen J, McGlynn KA, Schonfeld S, et al.. Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 2007; 99: 533-44.
- De Wit R, Roberts JT, Wilkinson PM, de Mulder PHM, Mead GM, Fossa SD, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European EORTC-GTCCG and. J Clin Oncol 2001; 19: 1629-40.
- Saxman SB, Finch D, Gonin R, Einhorn LH. Long-term follow up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: The Indiana University experience. J Clin Oncol 1998; 16: 702-6.
- Nichols CR, Wiliams SD, Loehrer PJ, Greco FA, Crawford ED, Weetlaufer J, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group Protocol. J Clin Oncol 1991; 9: 1163-72.
- Fossa SD, Horwich A, Russell JM, Roberts JT, Cullen MH, Hodson NJ, et al. Optimal planning target volume for stage I testicular seminoma: A MRC randomized trial. J Clin Oncol 1999; 17: 1146.
- Jones WG, Fossa SD, Mead GM, Roberts JT, Sokal M, Horwich A, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I seminoma: A report on MRC Trial TE 18, EORTC Trial 30942. J Clin Oncol 2005; 23: 1200-8.
- Kovač V. Prevention of fertility disturbances in oncological male patients. Radiol Oncol 1996; 30: 286-90.
- Horwich A, Alsanjari N, A´Hern R, Nicholls J, Dearnaley DP, Fisher C. Surveillance following orchidectomy for stage I testicular seminoma.Br J Cancer 1992; 65: 775-8.
- Van den Belt-Dusebout AW, Nuver J, de Wit R, Gietema JA, ten Bokkel Huinink WW, Rodrigus PT, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006; 24: 467-75.
- Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: A 20-year follow-up study. J Clin Oncol 2010; 28: 4649-57.
- Raghavan D, Cox K, Childs A, Grygiel J, Sullivan D. Hypercholesterolemia after chemotherapy for testis cancer.J Clin Oncol 1992; 10: 1386-9.
- Sagstuen H, Aass N, Fossa SD, Dahl O, Klepp O, Wist EA, et al. Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol 2005; 23: 4980-90.
- Nord C, Fossa SD, Egeland T. Excessive annual BMI increase after chemotherapy among young survivors of testicular cancer.Br J Cancer 2003; 88:36-41.
- Strumberg D, Brugge S, Korn MW, Koeppen S, Ranft J, Scheiber G, et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 2002; 13: 229-36.
- Meinardi MT, Gietema JA, van der Graaf WTA, van Veldhuisen DJ, Runne MA, Sluiter WJ, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18: 1725-32.
- Stoter G, Koopman A, Vendrik CP, Struyvenberg A, Sleyfer DT, Willemse PH, et al. Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol 1989; 7: 1099-104.
- Gietema JA, Sleijfer DT, Willemse PH, Schraffordt HK, van Ittersum E, Verschuren WM, et al. Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med 1992; 116: 709-15.
- Hanks GE, Peters T, Owen J. Seminoma of the testis: long-term beneficial and deleterious results of radiation. Int J Radiat Oncol Biol Phys 1992; 24:913-19.
- Zagars GK, Ballo MT, Lee AK, Strom SS. Mortality after cure of testicular seminoma. J Clin Oncol 2004; 22: 640-7.
- Fossa SD, Aass N, Harvei S, Tretli S. Increased mortality rates in young and middle-aged patients with malignant germ cell tumours. Br J Cancer 2004; 90: 607-12.
- Van den Belt-Dusebout AW, de Wit R, Gietema JA, Horenblas S, Louwmann MWJ, Ribot JG, et al. Treatment-specific risk of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007; 25: 4370-8.
- Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003; 21: 1513-23.
- Samuels BL, Vogelzang NJ, Kennedy BJ. Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy. Cancer Chemother Pharmacol 1987; 19: 253-6.
- Lederman GS, Sheldon TA, Chaffey JT, Herman TS, Gelman RS, Coleman CN. Cardiac disease after mediastinal irradiation for seminoma. Cancer 1987; 60: 772-6.
- Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996; 14:2923-32.
- Pedrinelli R, Giampietro O, Carmassi F, Melillo E, Dell´Omo G, Catapano G, et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994; 344: 14-18.
- Stehouwer CD, Yudkin JS, Fioretto P, Nosadini R. How heterogeneous is microalbuminuria in diabetes mellitus? The case for „benign“ and „malignant“ microalbuminuria. Nephrol Dial Transplant 1998; 13: 2751-4.
- Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-82.
- Nuver J, Smit AJ, Sleijfer DT, van Gessel AI, van Roon AM, van der Meer J, et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 2004; 40: 701-6.
- Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for fibrinolytic system as an independent primary risk factor. Circulation 1998; 98: 2241-7.
- Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996; 94: 2057-63.
- Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
- Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-97.
- Calabro P, Golia E, Yeh ET. CRP and the risk of atherosclerotic events. Semin Immunopathol 2009; 31: 79-94.
- Sellmayer A, Limmert T, Hoffmann U. High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or usefull screening? Int Angiol 2003; 22: 15-23.
- Nuver J, Smit AJ, van der Meer J, van den Berg MP, van den Graaf WTA, Meinardi MT, et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol 2005; 23: 9130-7.
- Gietema JA, Meinardi MT, Messerschmidt J, Gelevert T, Alt F, Uges DR, et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 2000; 355: 1075-6.
- Efstathiou E, Logothetis CJ. Review of late complications of treatment and late relapse in testicular cancer. J Natl Compr Canc Netw 2006; 4: 1059-70.
- Sprauten M, Darrah TH, Peterson DR, Campbell ME, Hannigan RE, Cvancarova M, et al. Impact of long-term serum platinum concentrations on neuro- and ototoxicity in cisplatin-treated survivors of testicular cancer. J Clin Oncol 2012; 30: 300-7.
- Verheij M, Dewit LG, Valdes Olmos RA, Arisz L. Evidence for a renovascular component in hypertensive patients with late radiation nephropathy. Int J Radiat Oncol Biol Phys 1994; 30: 677-83.
- Kim TH, Somerville PJ, Freeman CR. Unilateral radiation nephropathy – the long-term significance. Int J Radiat O ncol Biol Phys 1984; 10: 2053-9.
- Cassady JR. Clinical radiation nephropathy. Int J Radiat Oncol Biol Phys 1995; 31: 1249-56.
- Haugnes HS, Aass N, Fossa SD, Dahl O, Klepp O, Wist EA, et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 2007; 18: 241-8.
- Nuver J, Smit AJ, Wolffenbuttel BHR, Sluiter WJ, Hoekstra HJ, Sleijfer DT, et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer.J Clin Oncol 2005; 23: 3718-25.
- Gietema JA, Meinardi MT, van der Graff WT, Sleijfer DT. Syndrome X in testicular cancer survivors. Lancet 2001; 357: 228-9.
- Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Salonen R, et al. Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol 2003; 149: 601-8.
- Nord C, Bjoro T, Ellingsen D, Mykletun A, Dahl O, Klepp O, et al. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol 2003; 44: 322-8.
- Corn BW, Trock BJ, Goodman RL. Irradiation-related ischemic heart disease. J Clin Oncol 1990; 8: 741-50.
- Martinou M, Gaya A. Cardiac complications after radical radiotherapy. Semin Oncol 2013; 40: 178-85.
- Vasiliadis I, Kolovou G, Mikhailidis DP. Cardiotoxicity and cancer therapy. Angiol 2014; 65: 369-71.
- Celik T, Yuksel C, Demirkol S, Iyisoy A, Ulutin C. Coronary artery disease associated with radiation therapy. Cent Eur J Med 2010; 5: 180-3.
- Wethal T, Kjekshus J, Roislien J, Ueland T, Andreassen AK, Wergeland R, et al. Treatment-related differences in cardiovascular risk factors in long-term survivors of testicular cancer. J Cancer Surviv 2007; 1: 8-16.
- Haugnes HS, Bosl GJ, Boer H, Gietema JA, Brydoy M, Oldenburg J, et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow up. J Clin Oncol 2012; 30: 3752-63.
Language: English
Page range: 221 - 227
Submitted on: Feb 4, 2016
Accepted on: Feb 14, 2016
Published on: Apr 19, 2016
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Related subjects:
© 2016 Jasenka Gugic, Lorna Zadravec Zaletel, Irena Oblak, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.